355 related articles for article (PubMed ID: 23374189)
1. Biasing the parathyroid hormone receptor: relating in vitro ligand efficacy to in vivo biological activity.
Appleton KM; Lee MH; Alele C; Alele C; Luttrell DK; Peterson YK; Morinelli TA; Luttrell LM
Methods Enzymol; 2013; 522():229-62. PubMed ID: 23374189
[TBL] [Abstract][Full Text] [Related]
2. Refining efficacy: exploiting functional selectivity for drug discovery.
Gesty-Palmer D; Luttrell LM
Adv Pharmacol; 2011; 62():79-107. PubMed ID: 21907907
[TBL] [Abstract][Full Text] [Related]
3. Translating in vitro ligand bias into in vivo efficacy.
Luttrell LM; Maudsley S; Gesty-Palmer D
Cell Signal; 2018 Jan; 41():46-55. PubMed ID: 28495495
[TBL] [Abstract][Full Text] [Related]
4. Arrestins in bone.
Bohinc BN; Gesty-Palmer D
Prog Mol Biol Transl Sci; 2013; 118():335-58. PubMed ID: 23764060
[TBL] [Abstract][Full Text] [Related]
5. Parathyroid hormone (PTH) and PTH-related peptide domains contributing to activation of different PTH receptor-mediated signaling pathways.
Cupp ME; Nayak SK; Adem AS; Thomsen WJ
J Pharmacol Exp Ther; 2013 Jun; 345(3):404-18. PubMed ID: 23516330
[TBL] [Abstract][Full Text] [Related]
6. Emergent biological properties of arrestin pathway-selective biased agonism.
Appleton KM; Luttrell LM
J Recept Signal Transduct Res; 2013 Jun; 33(3):153-61. PubMed ID: 23448506
[TBL] [Abstract][Full Text] [Related]
7. Biased agonism at the parathyroid hormone receptor: a demonstration of functional selectivity in bone metabolism.
Bohinc BN; Gesty-Palmer D
Mini Rev Med Chem; 2012 Aug; 12(9):856-65. PubMed ID: 22681253
[TBL] [Abstract][Full Text] [Related]
8. β-Arrestin-biased signaling of PTH analogs of the type 1 parathyroid hormone receptor.
van der Lee MM; Verkaar F; Wat JW; van Offenbeek J; Timmerman M; Voorneveld L; van Lith LH; Zaman GJ
Cell Signal; 2013 Feb; 25(2):527-38. PubMed ID: 23159578
[TBL] [Abstract][Full Text] [Related]
9. Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling.
Hattersley G; Dean T; Corbin BA; Bahar H; Gardella TJ
Endocrinology; 2016 Jan; 157(1):141-9. PubMed ID: 26562265
[TBL] [Abstract][Full Text] [Related]
10. Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation.
Gesty-Palmer D; Chen M; Reiter E; Ahn S; Nelson CD; Wang S; Eckhardt AE; Cowan CL; Spurney RF; Luttrell LM; Lefkowitz RJ
J Biol Chem; 2006 Apr; 281(16):10856-64. PubMed ID: 16492667
[TBL] [Abstract][Full Text] [Related]
11. β-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo.
Gesty-Palmer D; Yuan L; Martin B; Wood WH; Lee MH; Janech MG; Tsoi LC; Zheng WJ; Luttrell LM; Maudsley S
Mol Endocrinol; 2013 Feb; 27(2):296-314. PubMed ID: 23315939
[TBL] [Abstract][Full Text] [Related]
12. Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34).
Wang L; Quarles LD; Spurney RF
J Bone Miner Res; 2004 Oct; 19(10):1661-70. PubMed ID: 15355561
[TBL] [Abstract][Full Text] [Related]
13. β-arrestin-biased agonism at the parathyroid hormone receptor uncouples bone formation from bone resorption.
Bohinc BN; Gesty-Palmer D
Endocr Metab Immune Disord Drug Targets; 2011 Jun; 11(2):112-9. PubMed ID: 21476967
[TBL] [Abstract][Full Text] [Related]
14. Tuberoinfundibular peptide (7-39) [TIP(7-39)], a novel, selective, high-affinity antagonist for the parathyroid hormone-1 receptor with no detectable agonist activity.
Hoare SR; Usdin TB
J Pharmacol Exp Ther; 2000 Nov; 295(2):761-70. PubMed ID: 11046116
[TBL] [Abstract][Full Text] [Related]
15. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
Kondo H; Guo J; Bringhurst FR
J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
[TBL] [Abstract][Full Text] [Related]
16. β-catenin regulates parathyroid hormone/parathyroid hormone-related protein receptor signals and chondrocyte hypertrophy through binding to the intracellular C-terminal region of the receptor.
Yano F; Saito T; Ogata N; Yamazawa T; Iino M; Chung UI; Kawaguchi H
Arthritis Rheum; 2013 Feb; 65(2):429-35. PubMed ID: 23124878
[TBL] [Abstract][Full Text] [Related]
17. Refining efficacy: allosterism and bias in G protein-coupled receptor signaling.
Luttrell LM; Kenakin TP
Methods Mol Biol; 2011; 756():3-35. PubMed ID: 21870218
[TBL] [Abstract][Full Text] [Related]
18. Arrestin pathways as drug targets.
Luttrell LM
Prog Mol Biol Transl Sci; 2013; 118():469-97. PubMed ID: 23764065
[TBL] [Abstract][Full Text] [Related]
19. Quantification of ligand bias for clinically relevant β2-adrenergic receptor ligands: implications for drug taxonomy.
van der Westhuizen ET; Breton B; Christopoulos A; Bouvier M
Mol Pharmacol; 2014 Mar; 85(3):492-509. PubMed ID: 24366668
[TBL] [Abstract][Full Text] [Related]
20. Disruption of β-catenin binding to parathyroid hormone (PTH) receptor inhibits PTH-stimulated ERK1/2 activation.
Yang Y; Wang B
Biochem Biophys Res Commun; 2015 Aug; 464(1):27-32. PubMed ID: 26047699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
